Background Information and Q&A
for Patients and Physicians Regarding AMEVIVE
(source:  Waggener Edstrom, for Biogen Idec, 10/12/2005)

Background

On September 8, 2005 Biogen Idec announced a comprehensive strategic reorganization of the company.  As a part of that reorganization, it decided to sell its psoriasis medication AMEVIVE.  The following attempts to address some of the questions patients and physicians have had, and to provide a bit more context around this business decision.  

Please visit our website (www.biogenidec.com) for a copy of the press release discussing this decision and updates regarding the sale of AMEVIVE. 

Q&A (as of 10/12/2005)

Q:  Why is Biogen Idec selling AMEVIVE?
A:  The decision to sell AMEVIVE was part of the company’s strategic business plan.  However, Biogen Idec employees still have a firm commitment to patients who are using and benefiting from the product and are actively seeking an appropriate new home for AMEVIVE.

Q:  Are you looking for a buyer?
A:  Yes.  The company is actively seeking a buyer, and would consider buyers that have existing dermatology products, expertise and sales/marketing infrastructure, or those that are willing and prepared to support the creation of such an infrastructure. 

Q:  Will this transition affect my ability to obtain the product?
A:  No.  Biogen Idec is prepared to offer to manufacture AMEVIVE for the new owner.  This will allow any purchaser to provide a proven supply of product.

Q:  Isn’t Biogen Idec closing its North Carolina plant?
A:  No.  Production is continuing as usual at the plant which manufactures AMEVIVE. 

Q:  What about customer service?  Will the hotline and other patient support groups still be up and running?
A:  Normal sales, customer service and medical support will continue.  It is the company’s goal to ensure that physicians and patients are not affected during this period.   

Q:  Should my doctor pre-order product, and if so, how long will it last?
A:  Pre-ordering is not necessary.  Product supply and availability is at no risk.  

Q:  What about ongoing clinical trials and possible therapeutic expansions? 
A:  Biogen Idec will continue to fund clinical studies in progress.

Q:  I’d like to learn more about AMEVIVE.  Where’s the best place to go?
A:  Check out the patient section on our website at http://www.amevive.com

Contents

www.flakehq.com